OGEN: חוב לטווח קצר של החברה Oragenics

Oragenics, Inc. (OGEN) vaccine development is independent of economic cycles or GDP, demonstrating high resilience to crises. Unique patents in intranasal agents against viral brain lesions protect the company from price wars. The share price retrospective with the 0.00 indicator is presented below. The business relies on the creation of innovative drug delivery methods in US laboratories and a promising pipeline of new drugs.

Identifying fundamentally resilient assets requires a liquidity analysis based on the sum of all liabilities and notes payable maturing within one year. Current borrowings amounting to 0.00 measure the ability of Oragenics, Inc. (OGEN) to service its debt, which is critical given the binary risks of a biotech pipeline and the company's total dependence on external financing for survival, as reflected in this chart.